KYTX
HEALTHCAREKyverna Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving KYTX Today?
No stock-specific AI insight has been generated for KYTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.47
Fundamentals
Trading
KYTX News
20 articles- Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial OfficerYahoo Finance·May 4, 2026
- Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLAMarketbeat·Apr 25, 2026
- Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingGlobeNewswire Inc.·Apr 21, 2026
- Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksYahoo Finance·Apr 20, 2026
- Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026Yahoo Finance·Apr 9, 2026
- The Oncology Institute Names Minh Merchant Chief Legal OfficerYahoo Finance·Apr 6, 2026
- Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 26, 2026
- Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026Yahoo Finance·Mar 5, 2026
- Kyverna Therapeutics to Participate in Upcoming March Investor ConferencesYahoo Finance·Mar 3, 2026
- Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of DirectorsYahoo Finance·Feb 24, 2026
- Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year247 Wall St·Feb 16, 2026
- Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology OfficerYahoo Finance·Feb 3, 2026
- Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 12, 2026
- Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Kyverna Therapeutics Stock Up 41% in a Month: Here's WhyYahoo Finance·Dec 30, 2025
- Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class ProspectsYahoo Finance·Dec 18, 2025
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockYahoo Finance·Dec 17, 2025
- Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation DataYahoo Finance·Dec 17, 2025
- Investors Parse Jobs Data, Look Ahead to Inflation Report as US Futures Rise Pre-BellYahoo Finance·Dec 17, 2025
- KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study DataYahoo Finance·Dec 16, 2025
All 20 articles loaded
Price Data
52-Week Range
$9.47
Fundamentals
Trading
About Kyverna Therapeutics Inc
Kyverna Therapeutics, Inc. is a pioneering biotechnology firm dedicated to developing advanced immunotherapies targeting autoimmune diseases and critical medical conditions. Leveraging its proprietary genetically engineered T-cell technology, the company seeks to bolster the immune system's efficacy, providing targeted therapeutic solutions for improved disease management. With a strong emphasis on cellular therapies, Kyverna is strategically positioned in the biopharmaceutical sector, presenting substantial opportunities for institutional investors eager to engage in innovative treatments and benefit from the expanding immunotherapy market.